Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 16/20 | 0.64 |
| ▸ | MET | P08581 | 11/20 | 0.64 |
| ▸ | JAK3 | P52333 | 4/20 | 0.58 |
| ▸ | JAK2 | O60674 | 1/20 | 0.58 |
| ▸ | JAK1 | P23458 | 1/20 | 0.58 |
| ▸ | TTK | P33981 | 1/20 | 0.58 |
| ▸ | INSR | P06213 | 2/20 | 0.57 |
| ▸ | EGFR | P00533 | 1/20 | 0.57 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.57 |
| ▸ | ROS1 | P08922 | 1/20 | 0.57 |
| ▸ | FER | P16591 | 1/20 | 0.57 |
| ▸ | LTK | P29376 | 1/20 | 0.57 |
| ▸ | BLK | P51451 | 1/20 | 0.57 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.57 |
| ▸ | BTK | Q06187 | 1/20 | 0.57 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.57 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.57 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.57 |
| ▸ | EML4 | Q9HC35 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2595197 | 0.89 | ALK (0.78) | ALKMETEGFR | |
| SCHEMBL12179324 | 0.85 | ALK (0.67) | ALKMETINSREGFRERBB2 | |
| SCHEMBL2594840 | 0.83 | ALK (0.60) | ALKMETINSREGFRROS1 | |
| SCHEMBL14982973 | 0.82 | ALK (0.71) | ALKMETINSREGFRERBB2 | |
| SCHEMBL14982975 | 0.82 | ALK (0.84) | ALKINSREGFRERBB2ROS1 | |
| SCHEMBL2588978 | 0.80 | ZAP70 (0.70) | ALKMETINSREGFRROS1 | |
| SCHEMBL29174720 | 0.79 | PTK2 (0.60) | ALKMETJAK3PTK2 | |
| SCHEMBL2595611 | 0.78 | EGFR (0.65) | ALKMETJAK3JAK2INSR | |
| SCHEMBL11916626 | 0.77 | ALK (0.77) | ALKMETPTK2 | |
| SCHEMBL12311987 | 0.76 | ALK (0.73) | ALKMETINSREGFRROS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160137610-A1 | Compounds that Modulate EGFR Activity and Methods for Treating or Preventing Conditions Therewith | Gatekeeper Pharmaceuticals, Inc. | 2016-05-19 | — | — | US | disclosed |
| US-20160137610-A1 | Compounds that Modulate EGFR Activity and Methods for Treating or Preventing Conditions Therewith | Gatekeeper Pharmaceuticals, Inc. | 2016-05-19 | — | — | US | disclosed |
| US-20130137709-A1 | Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith | Gatekeeper Pharmaceuticals, Inc. | 2013-05-30 | — | — | US | disclosed |
| US-20130137709-A1 | Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith | Gatekeeper Pharmaceuticals, Inc. | 2013-05-30 | — | — | US | disclosed |
| WO-2011140338-A1 | COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH | Gatekeeper Pharmaceuticals, Inc. (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137610-A1 | Compounds that Modulate EGFR Activity and Methods for Treating or Preventing Conditions Therewith | EGFR, ERBB2, BRCA1 | ALK 911/4885MET 8/4885JAK3 254/4885 |
| US-20130137709-A1 | Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith | EGFR, ERBB2, BRCA1 | ALK 911/4885MET 8/4885JAK3 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.